Glioblastoma response to standard treatment stratifies patients into two responder subtypes, creating the potential for precision medicine

Add to your list(s) Download to your calendar using vCal

• Dr Lucy Stead, University of Leeds
• Wednesday 22 November 2023, 11:00-12:00
• West Hub, West 2.

If you have a question about this talk, please contact Kirsty Shepherd.

Glioblastoma (GBM) brain tumours lacking IDH1 mutations (IDHwt) have the worst prognosis of all adult brain cancers. Patients receive surgery and chemoradiotherapy but tumours almost always fatally recur. Using RNAseq data from 107 pairs of pre- and post-standard treatment locally recurrent IDHwt GBM tumours, we identified two responder subtypes based on therapy-driven changes in gene expression. In two thirds of patients a specific subset of genes is up-regulated from primary to recurrence (Up responders) and in one third the same genes are down-regulated (Down responders). Characterisation of the responder subtypes indicates subtype-specific adaptive treatment resistance mechanisms. In Up responders treatment enriches for quiescent proneural GBM stem cells and differentiated neoplastic cells with increased neurotransmitter signalling, whereas Down responders commonly undergo therapy-driven mesenchymal transition. Stratifying GBM tumours by response subtype may lead to more effective treatment.

This talk is part of the Electrical Engineering series.

This talk is included in these lists:

• Electrical Engineering
• West Hub, West 2

Note that ex-directory lists are not shown.